Early diagnosis of chronic kidney diseases;Frühdiagnostik von chronischen Nierenerkrankungen

Internist

Volumn 46, Issue 4, 2005, Pages 378-388

  Schulze Lohoff, E ^a,b   Matthaus T ^a   Weber, M ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Klinikum Koln Merheim   (Germany)

Author keywords

Arterial hypertension; Diabetes mellitus; Early diagnosis; Microalbuminuria; Proteinuria

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CHRONIC KIDNEY DISEASE; DISEASE COURSE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; REVIEW;

CHRONIC DISEASE; DIAGNOSTIC ERRORS; HUMANS; KIDNEY DISEASES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 17844378013     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-005-1367-z     Document Type: Review

References (22)

1. Riegel W, Hahn K, Kreutz R, Weber M, Zidek W, Schmieder R (2005) Benefit Niere - Bedeutung eines Nephrologie-Screenings für Interventionsbeginn und Therapieerfolg. Dtsch Med Wochenschr (im Druck)
2. Nickolas TL, Frisch GD, Opotowsky AR, Arons R, Radhakrishan J (2004) Awareness of kidney disease in the US population: findings from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000. Am J Kidney Dis 44: 185-197
3. Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, Powe NR (2002) The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med 137: 479-486
4. Keane WF, Eknoyan G for the nKF PARADE Committee (1999) Proteinuria, Albuminuria, Risk, Assessment, Detection, Elimination (PARADE): a position paper of the national kidney foundation. Am J Kidney Dis 33: 1004-1010
5. Hildebrandt F, Otto E (2000) Molecular genetics of nephronophthisis and medullary cystic kidney disease. J Am Soc Nephrol 11: 1753-1761
6. Jais JP, Knebelmann B, Giatras I et al. (2000) X-linked Alport syndrome: Natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol 11: 649-657
7. De Jong PE, Brenner BM (2004) From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria. Kidney Int 66: 2109-2118
8. Walter U, Noeske U, Plaumann M, Haferkamp A, Krauth C, Dörning H (2004) Check-up 35 wieder in der Diskussion? Gesundheitswesen DOI: 10.1055/s-2004-833871
9. Frei U, Schober-Halstenberg HJ (2003) Nierenersatztherapie in Deutschland, QuaSi-Niere Jahresbericht 2002/2003. Berlin
10. Ritz E, Orth SR (1999) Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341: 1127-1133
11. Hasslacher C, Danne T, Sawicki P, Walter H (1999) Frühdiagnose der diabetischen Nephropathie. Dtsch Ärztebl 96: A-51
12. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462
13. Brenner BM, Cooper ME, de Zeeuw D et al.; RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869
14. Parving HH, Lehnert H, Brochner-Mortenson J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group (2001) The effects of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878
15. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952-1961
16. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330: 877-884
17. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350: 971-980
18. Schädlich PK, Brecht JG, Weber M, Ritz E, Rangoonwala B, Huppertz E (2002) Gesundheitsökonomische Relevanz einer Ramipril-Intervention bei Patienten mit nichtdiabetogener Nephropathie und Hypertonie. Nieren Hochdruckkr 31: 128-135
19. Hillege HL, Fidler V, Diercks GF et al.; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106: 1777-1782
20. Anavekar NS, McMurray JJ, Velazquez EJ et al. (2004) Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295
21. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305
22. Hostetter TH (2004) Chronic kidney disease predicts cardiovascular disease. N Engl J Med 351: 1344-1346